Edition:
India

Michael Erman

Lilly says diabetes drug Trulicity reduces heart risks in trial

05 Nov 2018

Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes, according to results of a large clinical trial.

AbbVie sees hit to Humira sales from European competition

02 Nov 2018

U.S. drugmaker AbbVie Inc on Friday lowered its forecast for overseas sales of its top-selling medicine, Humira, due to larger-than-expected pricing cuts because of new competition in Europe.

Pfizer revenue worse than expected as generic competition weighs

30 Oct 2018

Pfizer Inc on Tuesday reported worse-than-expected third quarter revenue and lowered the top end of its full-year sales forecast as generic competition and drug pricing pressure in the United States hurt its older drugs business.

Novartis, Pfizer join forces on potentially lucrative fatty liver disease

29 Oct 2018

ZURICH/NEW YORK Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics.

Trump seeks to base Medicare drug prices on lower overseas rates

26 Oct 2018

WASHINGTON/NEW YORK U.S. President Donald Trump, taking aim at "global freeloading," said on Thursday his administration would seek to lower prescription drug prices by basing what the government's Medicare program pays for some medications on the lower prices paid in other countries.

Merck, Bristol-Myers profits rise on cancer drug sales

25 Oct 2018

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

WRAPUP 1-Merck, Bristol-Myers profits rise on cancer drug sales

25 Oct 2018

Oct 25 Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

Bristol-Myers profit rises on better-than-expected cancer drug sales

25 Oct 2018

NEW YORK Bristol-Myers Squibb Co on Thursday posted better-than-expected third quarter profit and raised its full-year earnings forecast on strong demand for its cancer immunotherapy drugs.

Bristol-Myers profit rises on better-than-expected cancer drug sales

25 Oct 2018

NEW YORK, Oct 25 Bristol-Myers Squibb Co on Thursday posted better-than-expected third quarter profit and raised its full-year earnings forecast on strong demand for its cancer immunotherapy drugs.

Cost of blood pressure drug surges in U.S. after recall

17 Oct 2018

NEW YORK Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States in September, following a recall of much of the drug's supply.

World News